key: cord-0019639-0ys5ezht
authors: Díaz-Zagoya, Juan C.; Marín-Medina, Alejandro; Zetina-Esquivel, Alma M.; Blé-Castillo, Jorge L.; Castell-Rodríguez, Andrés E.; Juárez-Rojop, Isela E.; Miranda-Zamora, Rodrigo
title: Effects of high rosuvastatin doses on hepatocyte mitochondria of hypercholesterolemic mice
date: 2021-08-04
journal: Sci Rep
DOI: 10.1038/s41598-021-95140-1
sha: c0bc52f60545ab96f6f91926b32a3d6b0b6b3e4b
doc_id: 19639
cord_uid: 0ys5ezht

Statins are the cornerstone of therapy for individuals with hyperlipidemia. The aim of this study was to analyze the undesirable effects of mild, moderate and high doses of rosuvastatin in CD-1 male mice who received a cholesterol-rich diet, focusing on the morphological and functional changes on hepatocyte mitochondria. In a mouse model we studied the combined administration of a cholesterol-rich diet along with mild and moderate doses of rosuvastatin (1, 2.5 or 5 mg/kg/day) during several days. After the animals were sacrificed, liver mitochondria were isolated for microscopic studies and to analyze the respiratory function. The respiratory control (state-3/state-4) was evaluated in mice who received high doses of rosuvastatin. Rosuvastatin doses higher than 20 mg/kg/day induced premature death in mice with a hypercholesterolemic diet, but not in mice with a cholesterol-free diet. Doses from 2.5 to 5 mg/kg/day also induced morphological and functional alterations in mitochondria but these hypercholesterolemic animals survived longer. Giving 1 mg/kg/day, which is close to the maximal therapeutic dose for humans, did not affect mitochondrial architecture or respiratory function after two months of treatment. We analyzed the effect of rosuvastatin on hepatic tissue because it is where statins are mainly accumulated and it is the main site of endogenous cholesterol synthesis. Our results contribute to understand the side effects of rosuvastatin in hypercholesterolemic mice, effects that could also affect humans who are intolerant to statins.

www.nature.com/scientificreports/ Animal models can be used to evaluate and compare the side effects of statins 16 . One of the first adverse effects reported is that of lovastatin in rabbits 17 , which was aggravated when a cholesterol-rich diet was added. Some studies have used rodent models to analyze the statins side effects in hypercholesterolemic animals 18, 19 .

Our study provides data of mice who received a cholesterol-rich diet along with mild, moderate and high doses of rosuvastatin. We particularly looked for adverse effects on liver mitochondria of mice who received a cholesterol-rich-diet in comparison with mice who received a cholesterol-free diet and the same doses of rosuvastatin.

According to their solubility, the statins employed in patients are divided in two groups, the lipophilic constituted by fluvastatin, lovastatin, simvastatin and pitavastatin, and the hydrophilic integrated by rosuvastatin and pravastatin. It was chosen for this study rosuvastatin that is widely used by clinicians 20 . CD-1 male mice of 30 g body weight were maintained in light-dark cycles of 12 h. They received a laboratory chow diet (CD) containing 18% protein, 5% fat and 5% fiber. The food was powdered and rosuvastatin was added; then, food and statin were administered orally. The hypercholesterolemic diet (HD) contained 2% cholesterol and 0.6% sodium deoxycholate. Rosuvastatin tablets of 20 mg were obtained from Medimart, Slovenia. All other compounds were purchased from Merck-Sigma Mexico.

It was also included CD and HD animals that did not receive rosuvastatin (n = 6 per group). The experimental procedures followed the Official Mexican Standard NOM-062- ZOO-1999 CD + Ro (rosuvastatin 0, 20 mg/kg/day). HD + Ro (rosuvastatin 0, 20 mg/kg/day).

C. Mice who received a continuous treatment with mild doses of statin to evaluate hepatocytes mitochondrial respiration and to perform microscopic observations in representative samples of each group after different treatment lengths for 60 days:

HD + Ro (rosuvastatin 0, 5 mg/kg/day). HD + Ro (rosuvastatin 0, 2.5 mg/kg/day). HD + Ro (rosuvastatin 0, 1 mg/kg/day).

Animal sacrifice. After the treatment indicated in the experimental design, all animals were sacrificed employing a guillotine 21 . Blood and other tissues were immediately obtained for biochemical analysis or microscopic studies.

Mitochondria isolation and incubation. The liver was homogenized in 250 mM sucrose, 0.5 mM HEPES, 0.5 mM EGTA (SHE) at pH 7.2 and using a Thomas pestle tissue grinder (piston-type Teflon pestle). The liver was homogenized with a soft manual procedure in order to generate the minor damage to mitochondria; then, mitochondria were isolated using a refrigerated centrifuge MPW-353R Med Instruments, Warsaw, following the method described by Frezza et al. 22 . The mitochondria obtained by centrifugation were incubated for 10 min with 0.5% albumin to eliminate fatty acids; then, they were re-suspended in SHE solution. The protein content in mitochondria was evaluated by the Bradford method 23 . The incubation media contained: KCl 240 mM, HEPES 60 mM, H 3 PO 4 4 mM, EGTA 4 mM, Succinate 10 mM, MgCl 2 4 mM, mitochondrial protein 4 mg, at pH 7.2, final volume 3.2 ml. An YSI oxygen meter 5300 model was used to measure the oxygen consumption. The mitochondrial respiration was stimulated by adding 10 µL of 200 mM ADP 24 . And the respiratory control was evaluated.

Biochemical parameters. Serum determinations included total cholesterol, triacylglycerols, HDL-C (high density lipoprotein cholesterol), glucose, urea, creatinine, AST (aspartate aminotransferase) and ALT (alanine aminotransferase). We used a semi-automatic equipment of clinical chemistry from Random Access Diagnostics. Besides, the 3-hydroxy-methylglutaryl-CoA/mevalonate ratio was evaluated, this index determines the activity of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase 25 www.nature.com/scientificreports/ copy the mitochondrial pellet and liver tissue were fixed with 3% glutaraldehyde in cacodylate buffer. The samples were processed at the microscopy unit of the "Instituto de Neurobiología, Universidad Nacional Autónoma de México", using a Jeol transmission electron microscope model JEM-1010.

Statistical analysis. The mice survival was expressed in percentages. One-way analysis of variance (ANOVA), followed by Student-Newman-Keuls test and differences were considered statistically significant when p < 0.05. For morphologic analysis we used representative samples from each of the animal groups.

Biochemical parameters. Serum triacylglycerols decreased after receiving HD + Ro 20 mg/kg/day on day 3 (47 ± 2.82 mg/dL) and day 5 (53 ± 0.80 mg/dL) versus HD without Ro (97 ± 2.82 mg/dL). Conversely, serum cholesterol levels increased significantly on days 3 and 5 (761.5 ± 0.7 mg/dL and 813 ± 1.06 mg/dL, respectively) versus HD without Ro (202 ± 5.65 mg/dL). HDL-C decreased after receiving HD + Ro 20 mg/kg/day on days 3 and 5 (16 ± 1.06 mg/dL and 14 ± 0.14 mg/dL, respectively) compared with HD without Ro (59.2 ± 0.63 mg/ dL) ( Table 1 ). An unexpected result was the disturbing decrease in ALT and AST serum activity that was almost undetected on days 3 and 5 after treatment (1.67 ± 0.29 IU/L; 1.93 ± 0.52 IU/L, and 2.33 ± 0.64 IU/L, 2.17 ± 0.60 IU/L; respectively) ( Table 1) . Regarding the respiratory function, it decreased after 3 and 5 days of receiving HD + Ro 2.90 ± 0.56 and 0.95 ± 0.63) in comparison with HD without Ro (3.05 ± 0.07) ( Table 2 ). The 3-hydroxy-methylglutaryl-CoA/mevalonate ratio, which was high after 3 days of HD + Ro treatment, and even higher after 5 days of treatment (3.93 ± 1.30), versus the HD without Ro group (2.53 ± 0.31) (p < 0.05) (Fig. 1) . These data reveal that rosuvastatin decreased the activity of 3-hydroxy-3-methylglutaryl-CoA reductase. Table 3 shows the mice survival rate when using different doses of rosuvastatin. The combined administration of Ro and a cholesterol-rich diet produced a premature death with doses 20 mg/kg/day or higher of rosuvastatin. However, there was no-mortality in animals without a cholesterol-rich diet that received the same statin doses. In this context, studies performed by Diaz-Zagoya et al., 18, 19 showed that high doses of statins administered in a period of 30-60 days in a mouse model without a high-cholesterol diet had a survival rate of 100%.

A 20 mg/kg/day dose of Ro was tested in mice receiving CD or HD. Animals in the HD + Ro group were sacrificed on days 1, 3 and 5 of treatment. A daily analysis was performed in order to observe any morphologic changes in hepatocytes and the respiratory function of mitochondria. The body weigh was registered, as well as the liver weigh in relation to the body weight. Macroscopically, livers of the animal group treated with statins were friable with appearance of steatosis. Table 4 shows that the liver weight of animals who received HD + Ro 20 mg/kg/day increased significantly after 3 and 5 days of treatment. In this regard, previous studies performed by Diaz-Zagoya et al., 18, 19 showed that no significant changes were observed on day 1 and 3. However, an increase in the weight of the mice www.nature.com/scientificreports/ liver in relation to body weight was observed in CD + Ro 5 mg/kg/day, this difference was not significant with respect to CD. An increase in the weight of mice liver in relation to body weight was observed in the CD + Ro group, but it was not significant with respect to the CD and HD group.

Microscopy observations. Liver tissue was stained with hematoxylin/eosin and evaluated after 1, 3 and 5 days of treatment with HD + Ro 20 mg/kg/day. Liver tissue of CD + Ro 20 mg/kg/day (Fig. 2B) or HD (Fig. 2C ) showed no alteration compared to liver tissue of CD without Ro ( Fig. 2A) . Livers of mice who received HD + Ro 20 mg/kg/day, after 1 to 5 days of treatment, showed early steatosis with abundant lipid drops and severe changes such as ballooning degeneration, Mallory Denk bodies and hepatocytes with loss of nuclei. No necrosis was observed ( Fig. 2D-F ).

Rosuvastatin doses of 0, 1, 2.5 and 5 mg/kg/day were used during different periods of time. Mice were sacrificed every day and the morphological and physiological evaluations were performed. Animals that received HD + Ro 5 mg/kg/day did not show important differences in their body weight in comparison with other groups; however, their liver weight increased significantly from day 5 on, a fact that was highly apparent when we compared the percentage of liver weight relative to body weight ( www.nature.com/scientificreports/ 59. On the other hand, animals treated with HD + Ro 1.0 mg/kg/day, did not show alterations of the mitochondrial function even after 59 days of treatment (Table 5 ). It was observed that the HD + Ro 2.5 mg/kg/day group decreased respiratory control (1.80) with respect to the HD group (3.22) , this result is similar to the group that received a dose of 5 mg/kg/day (1.79); at the same period of treatment on 5 days ( Table 5 ). The HD + Ro 5 mg/kg/day treatment (Fig. 3A ) was observed to be harmful to mitochondria, showing loss of architecture pattern, some had a donut-like shape and matrixes with empty spaces. The HD + Ro 2.5 mg/kg/day treatment (Fig. 3B ) displayed copious mitochondrial damage and disorganized organelle structure. Mitochondria obtained after 59 days of HD + Ro 1 mg/kg/day treatment (Fig. 3C) showed a general conserved structure with few organelles having a horseshoe aspect. Mitochondria in Fig. 3D -F are the corresponding controls.

Rosuvastatin is a powerful synthetic statin that is not exempted of undesirable effects in doses regularly used in humans. If a human of 70 kg body weight, receives a rosuvastatin dose of 40 mg/day, he or she is receiving 0.57 mg/kg/day. We administered different doses to mice, the smallest was equivalent to 1 mg/kg/day; higher doses produced several undesirable effects in our mice model, especially in the liver, the main site of statin accumulation. The 400 mg dose had a 100% mortality after 6 days of treatment, a result that could be explained by the damage, non-compatible with life, produced on mitochondria structure and function; therefore, a moderate-high dose was considered to be 20 mg/kg/day and the mild to moderate doses between 1 and 5 mg/kg/day.

Although some studies have shown that rosuvastatin significantly reduces serum cholesterol concentrations by using lyophilized tablets 26 , we observed an increase in serum cholesterol on days 3 and 5 (761.5 ± 0.7 mg/dL and 813 ± 1.06 mg/dL, respectively) in the HD + Ro group versus the HD without Ro group (202 ± 5.65 mg/dL). Previous studies have already reported that undesirable effects of statins are aggravated if a diet rich in cholesterol is added 17 . The combination of HD + Ro can modify the dynamics of the cholesterol metabolism genes, since when cholesterol concentrations increase, the catalytic release of SREBP2 proteins is blocked, which are important transcription factors for the expression of many genes such as the hepatic LDL receptor (LDLR) 27 . Therefore, having a HD diet could influence the expression of these genes by decreasing the amount of LDLR in the liver, so the amount of cholesterol that reaches the liver could be reduced and redistributed in plasma and other tissues.

Other studies have reported an increase in serum cholesterol due to the use of rosuvastatin, it has been observed that mice treated with Ro had an increase in total serum cholesterol; and although Ro has been observed to cause an increase in hepatic LDL receptor messenger RNA in humans, the opposite effect has been observed in rats 28 . Therefore, the amount of this protein in the liver decreases and the serum concentration of cholesterol increases. This result supports the increase in serum cholesterol found in our study from the third day of treatment with Ro; therefore, this double effect could explain the increase in cholesterol in mice treated with HD + Ro.

Undesirable side effects have also been reported in human skeletal muscle where myositis and even rhabdomyolysis have been observed 29 . Although the use of low-dose statins helps to restore the histological architecture of the liver in individuals with NAFLD 30 , it has also been observed that in individuals with complicated sepsis, statins appear to accelerate liver damage. In this sense, we observed that Ro at low doses (1 mg) did not significantly affect respiratory function, even in a prolonged treatment (59 days) compared with doses of 5 and 2.5 mg Table 4 . Liver weight and its relation to body weight in hypercholesterolemic mice treated with 20 and 2.5 mg/kg/day of rosuvastatin, after days of treatment. CD control diet; HD hypercholesterolemic diet; Ro rosuvastatin 20 mg/kg/day; Ro rosuvastatin 2.5 mg/kg/day, M media, SD standard deviation. a Key of significance compared with HD (p < 0.05). www.nature.com/scientificreports/ that significantly affected respiratory function from day 5. A study on mice with dystrophin protein deficiency who received 10 mg/kg of rosuvastatin, showed significantly increased areas of myonecrosis and inflammation, while mice without altered dystrophin who received the same doses showed increased levels of NF-Κβ, TNF-α as well as increased creatine kinase activity 31 , which suggests that high doses of rosuvastatin could potentiate the expression of some genes that encode proteins of inflammation pathways. In this sense, some authors presented that Rosuvastatin increases the expression of IL-10, and inhibits the overexpression of NF-κB 32, 33 . Besides, there is evidence to suggest that statins inhibit the Myd88 pathway and therefore suppress the NF-κB pathway 34 . Besides the cholesterol-lowering effect of statins, it has been suggested that statins can be used as an associated therapy for COVID-19 due to their anti-inflammatory action that might reduce the risk of cardiovascular complications caused by SARS-CoV-2 virus 35, 36 . Therefore, rosuvastatin and other statins are under a close examination. www.nature.com/scientificreports/ In this study, we observed that high doses of rosuvastatin affected liver mitochondria architecture and mitochondrial respiration. We compared the oxygen consumption in states 3 and 4 of respiration; phosphorylation in state 3 was stimulated by adding 200 mM ADP to the incubation medium. The state 3/state 4 ratio decreased when mice received rosuvastatin doses of 2.5 mg/kg/day or higher. Previous studies using high doses of simvastatin in rats and humans have reported a decreased function of complex I in the respiratory chain 37 which considerably decreases the flow of electrons from NADH towards complex III. Therefore, under these conditions the mitochondrial energy load would depend mostly of the electron flow from FADH to complex II, resulting in a lower production of ATP by the ATP synthase. Additionally, the inhibition of the 3-hydroxy-3 methyl glutaryl CoA reductase decreases the formation of coenzyme Q 38 , essential for the transport of electrons to complex III and would affect the Q cycle in this complex, which is important for the regeneration of coenzyme Q. All these factors together contribute to a decrease in ATP synthesis.

Animal model studies have explored diseases that affect mitochondrial function altering the transport of metabolites to mitochondria (especially ADP) 39 . We did not explore the intimal mechanism of the respiratory chain alteration, but there is information regarding the changes that other statins induce in muscle mitochondrial function [40] [41] [42] . Moreover, a decrease in mitochondrial respiration was observed in rats treated with low doses of Rosuvastatin 1 mg/kg/day (not statistically significant); and a small decrease in respiration of the mitochondrial complex was also reported at the same doses, but without affecting the functioning of this complex 37 . We observed that the 3-hydroxy-3-methylglutaryl-CoA/mevalonate ratio in liver homogenate was high on day 3 and higher on day 5 of treatment; this result shows the inhibitory action of Ro on the HMG-CoA reductase enzyme. This inhibitory action of Ro on the main regulatory site of cholesterogenesis was not able to overthrow the effect of the cholesterol-rich diet on serum cholesterol levels.

The role of several molecules in inflammatory processes at mitochondrial level is already known. For instance, NF-Κβ plays a very important role in many mitochondria functions and it has been observed that its over-activation is related to inflammatory processes and cancer 43 . Furthermore, NF-Κβ is closely related to the functioning of antioxidant proteins expressed in mitochondria such as superoxide dismutase, catalase and glutathione peroxidase, which are important enzymes in the regulation of free radical genesis and proper functioning of mitochondrial energy metabolism 44 . On the other hand, rosuvastatin has been reported to have beneficial cardioprotective effects in mice who received mild doses; in high doses however, this effect is lost and even harmful effects have been observed 45 .

Rosuvastatin is minimally metabolized through CYP 450 enzymes 11 . An abnormal drug metabolism produces a large number of free radicals and lipid peroxidation resulting in oxidative stress and cells damage. In studies carried out in animal models, it was observed that the administration of statins in high doses for 8 weeks, decreased the activity of several enzymes related to oxidative stress (SOD, GHS and GR); therefore, a decrease in the activity of these enzymes could increase the production of free radicals. Besides, other additional mechanisms that may contribute to statin-induced oxidative stress have been observed: decreased activity of transporters (ABCB1 and ABCG2), activation of the caspase pathway, and decreased synthesis of coenzyme Q [ 11, 46 ] . In this sense, Rosuvastatin reduces serum lipids and cholesterol, resulting in CoQ 10 deficiency; CoQ 10 is the antioxidant that can protect biological membranes from free radicals and lipid peroxidation, and CoQ 10 deficiency might be traumatic after high doses of statins. In our study, a decrease in HDL-cholesterol was observed from day 3 of treatment with doses of 20 mg/kg/day; the dose-dependent effect of statins on LDL cholesterol reduction has previously been reported 47, 48 . However, another study showed a low increase in HDL-C and a decrease in the capacity for cholesterol efflux by the ABCA1 protein after treatment with atorvastatin 49 , which is important in the formation of HDL lipoproteins. Therefore, rosuvastatin in high doses could significantly affect the efflux of cholesterol by the ABCA1 protein and thus reduce the amount of HDL-C.

In electron microscopy, we observed rosette-shaped mitochondria, alterations in the inner membrane continuity and matrix with vacuous spaces. In light microscopy, hepatocytes with ballooning degeneration and cells with Mallory-Denk bodies were observed; from day 3 of treatment with HD + rosuvastatin at 20 mg/kg/day, these changes occurred in response to a severe depletion of ATP 50 and represent the macroscopic modifications that high doses of rosuvastatin have on mitochondrial metabolism. Table 5 . Oxygen consumption by liver mitochondria in hypercholesterolemic mice treated with rosuvastatin 1.0, 2.5 or 5 mg/kg/day, after 60 Days of Treatment. CD control diet, HD hypercholesterolemic diet, Ro rosuvastatin. 

HD + Ro in doses of 20 mg or higher produced premature death in our model; high rosuvastatin doses given to hypercholesterolemic mice produced severe changes in mitochondrial architecture and function, while low doses did not produce relevant changes in mitochondrial function or architecture. The combination of HD + Ro in our model increased the concentration of serum cholesterol and decreased that of HDL-C. More studies on www.nature.com/scientificreports/

The discovery and development of HMG-CoA reductase inhibitors

Lipid-lowering efficacy of rosuvastatin

Apoprotein B particles and cardiovascular disease: A narrative review

Rationale and design of randomized evaluation of aggressive or moderate lipid lowering therapy with pitavastatin in coronary artery disease (REAL-CAD) trial. Int

Effectiveness of interventions aimed at increasing statin-prescribing rates in primary cardiovascular disease prevention. A systematic review of randomized clinical trials

ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Statin use in primary prevention of atherosclerotic cardiovascular disease according to 5 major guidelines for sensitivity, specificity, and number needed to treat

Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment

Risk of cardiovascular events in patients with type 2 diabetes and metabolic dyslipidemia without prevalent atherosclerotic cardiovascular disease

Natural antihyperlipidemic agents: Current status and future perspectives

Statins: Adverse reactions, oxidative stress and metabolic interactions

Statin-associated side effects

Myotoxicity of statins: Mechanisms of action

Statin myotoxicity: A review of genetic susceptibility factors

Access and concentrations of atorvastatin in the prostate in men with prostate cancer

Models to study atherosclerosis: A mechanistic insight

Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits

High lovastatin doses combined with hypercholesterolemic diet induce hepatic damage and are lethal to the CD-1 mouse

Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet

Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update

Susceptibility to obesity and gallbladder stasis produced by a protein-and fat-enriched diet in male mice compared with female mice

Organelle isolation: Functional mitochondria from mouse liver, muscle and cultured fibroblasts

A rapid and sensitive methods for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Respiratory enzymes in oxidative phosphorylation. III. The steady state

Indirect assessment of hydroxymethylglutaryl-CoA reductase (NADPH) activity in liver tissue

Rosuvastatin lyophilized tablets loaded with flexible chitosomes for improved drug bioavailability, antihyperlipidemic and anti-oxidant activity

Srebp2: A master regulator of sterol and fatty acid synthesis

Rosuvastatin reduces aortic sinus and coronary artery atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ ApoE (Apolipoprotein E) double knockout mice independently of plasma cholesterol lowering

National heart, lung, and blood institute ARDS clinical trials network, rosuvastatin for sepsis-associated acute respiratory distress syndrome

The role of statins in the management of non-alcoholic fatty liver disease

Cardiac and skeletal muscle changes associated with rosuvastatin therapy in dystrophic mdx mice

Effects of simvastatin and rosuvastatin on RAS protein, matrix metalloproteinases and NF-κB in lung cancer and in normal pulmonary tissues

Rosuvastatin attenuates high-salt and cholesterol diet induced neuroinflammation and cognitive impairment via preventing nuclear factor KappaB pathway

Statins in COVID-19: Is there any foundation?

Cholesterol in relation to COVID-19: Should we care about it

Meta-analysis of effect of statins in patients with COVID-19

Statin-induced changes in mitochondrial respiration in blood platelets in rats and human with dyslipidemia

Preconditioning delays Ca 2+ -induced mitochondrial permeability transition

Altered expression of the adenine nucleotide translocase isoforms and decreased ATP synthase activity in skeletal muscle mitochondria in heart failure

Statin-induced mitochondrial dysfunction and targeting coenzyme Q 10 therapy

Statin treatment decreases mitochondrial respiration but muscle coenzyme Q10 levels are unaltered: the LIFESTAT study

Mitochondrial behavior, morphology, and animal performance

Nuclear transcription factors in the mitochondria: A new paradigm in fine-tuning mitochondrial metabolism

Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses

Rosuvastatin postconditioning protects isolated heart against ischemic-reperfusion injury: The role of radical oxygen species, PI3K-Akt-GSK-3β pathway and mitochondrial permeability transition pore

Assessment of hepatic function, oxidant/antioxidant status, and histopathological changes in rats treated with atorvastatin: Effect of dose and acute intoxication with acetaminophen

Pleiotropic effects of statins on the cardiovascular system

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

Niacin therapy increases high-density lipoprotein particles and total cholesterol efflux capacity but not ABCA1-specific cholesterol efflux in statin-treated subjects

Mallory-Denk body pathogenesis revisited

This study was supported in part by PAPIIT IN213718. The authors also thank Alejandra Gemila, Lourdes Palma and Hannah Groves for their assistance.

J.D.Z., conceptualization, methodology, fund acquisition, original draft preparation. I.E.J.R., conceptualization, supervision, fund acquisition, writing-reviewing; A.M.M., data curation, writing reviewing. A.Z.E. investigation; methodology. A.C.R., investigation, supervision; J.B.C., writing-reviewing. R.M., investigation.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-021-95140-1.Correspondence and requests for materials should be addressed to J.C.D.-Z. or I.E.J.-R.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.